Clinical Trial Update: A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CBX 12 in platinum-resistant or refractory ovarian cancer, sponsored by Cybrexa Therapeutics, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CBX-12

Snippet

Sponsor: Cybrexa Therapeutics | Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma | Phase 2 | Status: RECRUITING